RELATIONSHIP BETWEEN ANTI-MULLERIAN HORMONE AND BONE REMODELING MARKERS IN ELDERLY WOMEN WITH POLYCYSTIC OVARY SYNDROME

Abstract

The article presents data from a study investigating the impact of insulin resistance on bone mineral density and the dynamics of bone remodeling markers in women with polycystic ovary syndrome (PCOS) during the postmenopausal period. Additionally, the study evaluated the efficacy of anti-Müllerian hormone (AMH) as a predictor of bone changes in patients with PCOS. The study involved 128 women aged 45–65. The main group consisted of 85 women with PCOS, and the control group included 43 clinically healthy women. Research findings revealed that disruptions in carbohydrate metabolism and excessive androgen secretion persist in women with PCOS even after menopause. The study demonstrated that insulin resistance directly affects bone structure in women with PCOS, regardless of obesity status. This may help explain the higher bone density observed in patients with PCOS. Furthermore, elevated anti-Müllerian hormone levels in postmenopausal women with PCOS were associated with bone resorption markers, confirming a link with adaptive bone metabolism processes. However, further studies are necessary to elucidate the underlying mechanisms and to analyze the prognostic capabilities of anti-Müllerian hormone in assessing the condition of bone tissue in PCOS.